Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1265MR)

This product GTTS-WQ1265MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Glioblastoma multiforme (GBM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1265MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7408MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GA201
GTTS-WQ4074MR IVTScrip™ mRNA-Anti-IGF, BI 836(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI 836
GTTS-WQ3504MR IVTScrip™ mRNA-Anti-APP, BAN-2401(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAN-2401
GTTS-WQ11114MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MDX-060
GTTS-WQ12034MR IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MM-302
GTTS-WQ13508MR IVTScrip™ mRNA-Anti-SNCA, PRX002(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRX002
GTTS-WQ4271MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ10439MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY-2495655
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW